Henry Schein (HSIC)
(Delayed Data from NSDQ)
$70.34 USD
-0.33 (-0.47%)
Updated Jul 19, 2024 04:00 PM ET
After-Market: $70.35 +0.01 (0.01%) 7:58 PM ET
3-Hold of 5 3
A Value C Growth D Momentum B VGM
Price, Consensus and EPS Surprise
HSIC 70.34 -0.33(-0.47%)
Will HSIC be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for HSIC based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HSIC
Strength Seen in Henry Schein (HSIC): Can Its 5.4% Jump Turn into More Strength?
Is It Wise to Retain Henry Schein (HSIC) in Your Portfolio Now?
HSIC: What are Zacks experts saying now?
Zacks Private Portfolio Services
Henry Schein (HSIC) Banks on Strategic Buyouts Amid Macro Issues
4 Stocks to Buy Amid Dental Supplies Industry Challenges
What's in Store for Patterson Companies (PDCO) in Q4 Earnings?
Other News for HSIC
Henry Schein just upgraded at Baird, here's why
Fiduciary Management Q2 2024 Investment Strategy Outlook
Henry Schein Hosts Ribbon Cutting Ceremony to Celebrate New Southwestern Distribution Center
Henry Schein to Webcast Second Quarter 2024 Conference Call on Tuesday, August 6, 2024 at 10:00 a.m. ET
Analysts Offer Insights on Healthcare Companies: Amphastar Pharmaceuticals (AMPH), Verona Pharma (VRNA) and Henry Schein (HSIC)